Trial intelligence / Profile preview

Lian-Hua Qing-Ke Tablets for mild/common COVID-19

ChiCTR2100042069Phase 4Recruiting

Sponsor
Hebei Province Chest Hospital
Start
Jan 2021
Countries
1
01

Overview

Phase 4, randomised, open-label trial of Lianhua Qingke in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hebei Province Chest Hospital. Primary endpoint: Clinical symptom recovery rate and recovery time. Started Jan 2021; status: recruiting.

02

Drugs

Lianhua Qingke
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on ChiCTR2100042069.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2100042069.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call